FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2122262513> ?p ?o ?g. }

• W2122262513 endingPage "3853" @default.
• W2122262513 startingPage "3851" @default.
• W2122262513 abstract "Secondary involvement of the CNS by diffuse large B-cell lymphoma (DLBCL) occurs in less than 1% to more than 10% of patients with DLBCL depending on the presence or absence of five risk factors that compose the International Prognostic Index (age, elevated lactate dehydrogenase, poor performance status, advanced stage, and involvement of one extranodal site). Involvement of the kidneys and/or adrenal glands has been found to represent a site-specific additional risk factor for secondary CNS lymphoma (SCNSL). Other risk models have been proposed but not validated. It is also likely that molecular features of the tumor (eg, presence of MYC or BCL2 rearrangements, double-hit lymphomas) will add to or substitute for these clinical risk factors in the near future. SCNSL occurs early (frequently within weeks to months) after diagnosis of systemic disease; can affect the brain (or spinal cord and cranial nerves), the meninges, or both; and until recently, was almost always fatal. Because progression or relapse in the CNS occurs this early after diagnosis, most investigators believe that a significant number of patients prone to develop SCNSL harbor lymphoma cells in the brain parenchyma or the CSF at the time of diagnosis. Modern state-of-the-art techniques like magnetic resonance imaging or fluorescence-activated cell sorting analysis of CSF are much more sensitive in detecting SCNSL compared with clinical judgment, computed tomography scans, or microscopic interpretation of cytospin smears and probably would allow documentation of CNS involvement in an unknown but potentially significant number of patients scoring as CNS negative when traditional methodology is used. As a first step, however, consensus is needed regarding which patients are considered at high enough risk to warrant CNS-specific diagnostic approaches that will likely yield negative results in the majority of patients, will create discomfort, if not more serious adverse effects, in some patients, and will increase costs. The ability to identify patients with documented CNS disease could prompt immediate management with a CNS-specific treatment protocol, whereas patients who are CNS negative by magnetic resonance imaging and fluorescenceactivated cell sorting analysis (for instance) would receive immunochemotherapy like any other patient with DLBCL. Alternatively, the highest risk group might be candidates for CNS prophylaxis. With most retrospective analyses showing no benefit of intrathecal (IT) injections of cytotoxic drugs (methotrexate [MTX], cytarabine [Ara-C], prednisone, or combinations thereof), this prophylactic strategy can no longer be generally be recommended. If deemed necessary, more complex and more toxic approaches, such as administration of systemic high-dose MTX or combinations of cytotoxic drugs that cross the blood-brain barrier (BBB) as pioneered with the French doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone regimen, should be considered. Treatment of SCNSL with IT injections, whole-brain radiotherapy, or systemic administration of cytotoxic drugs that do not cross the BBB has largely been ineffective. Only when repeated courses of high-dose MTX and Ara-C were introduced did patients begin to show measurable benefit and survive significantly longer; cure, however, remained the exception to the rule. Until today, virtually all other drugs known to cross the BBB (procarbazine, etoposide, ifosfamide, thiotepa, carmustine [BCNU], and others) have been used mostly in combination with MTX and/or Ara-C to further improve results. As with MTX and Ara-C, most other drugs seem to be most effective at high doses, necessitating transplantation of autologous hematopoietic stem cells. Consequently, the most recent and successful protocols to treat primary and secondary CNS lymphoma consist of complex treatment algorithms encompassing two or more courses of high-dose MTX and/or Ara-C administered together with other BBB-crossing agents, followed by high-dose therapy combining BBB-crossing agents like BCNU, thiotepa, busulfan, oretoposide,whichcanbedoseescalatediftransplantationofhematopoietic stem cells ensues. The first prospective phase II study demonstrating the potential of this strategy was reported by Korfel et al. Patients up to age 65 years received induction chemotherapy with high-dose MTX, ifosfamide, and dexamethasone followed by high-dose Ara-C, thiotepa, and dexamethasone. Responding patients were consolidated with highdose therapy consisting of BCNU, thiotepa, and etoposide and transplantation of autologous blood stem cells. With this approach, the 2-year treatment failure rate was 49% 19% and the 2-year overall survival rate was 63% 19%. Another study was reported by Doorduyn et al in 2012; this study, which is not fully published yet, is of particular interest because for the first time rituximab was given with the cytotoxic agents. Because many patients with lymphoma experiencing relapse in the CNS had received rituximab as part of conventional first-line therapy until shortly before relapse and intravenous rituximab does not result in significant therapeutic concentrations in the CNS when the BBB is intact, early protocols including high-dose therapy/ASCT did not use rituximab or any other lymphoma-directed antibody. After it was appreciated that rituximab monotherapy can induce short-lived remissions in patients with CNS disease and thus must be able to penetrate into the CNS of JOURNAL OF CLINICAL ONCOLOGY E D I T O R I A L VOLUME 33 NUMBER 33 NOVEMBER 2" @default.
• W2122262513 created "2016-06-24" @default.
• W2122262513 creator A5002498295 @default.
• W2122262513 creator A5089156165 @default.
• W2122262513 date "2015-11-20" @default.
• W2122262513 modified "2023-09-27" @default.
• W2122262513 title "Advances in the Treatment of Secondary CNS Lymphoma" @default.
• W2122262513 cites W152497440 @default.
• W2122262513 cites W1860711823 @default.
• W2122262513 cites W1946301794 @default.
• W2122262513 cites W1993442932 @default.
• W2122262513 cites W1995939575 @default.
• W2122262513 cites W2017266004 @default.
• W2122262513 cites W2024292542 @default.
• W2122262513 cites W2025868687 @default.
• W2122262513 cites W2030286725 @default.
• W2122262513 cites W2030776533 @default.
• W2122262513 cites W2075456403 @default.
• W2122262513 cites W2092261723 @default.
• W2122262513 cites W2096047333 @default.
• W2122262513 cites W2100885061 @default.
• W2122262513 cites W2111322227 @default.
• W2122262513 cites W2113971895 @default.
• W2122262513 cites W2120766517 @default.
• W2122262513 cites W2122090895 @default.
• W2122262513 cites W2123971450 @default.
• W2122262513 cites W2126778627 @default.
• W2122262513 cites W2143536992 @default.
• W2122262513 cites W2147686446 @default.
• W2122262513 cites W2155495849 @default.
• W2122262513 cites W2162693374 @default.
• W2122262513 cites W2164995655 @default.
• W2122262513 cites W2166676098 @default.
• W2122262513 cites W2167425679 @default.
• W2122262513 cites W2472813907 @default.
• W2122262513 cites W2557250380 @default.
• W2122262513 doi "https://doi.org/10.1200/jco.2015.63.1143" @default.
• W2122262513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26282665" @default.
• W2122262513 hasPublicationYear "2015" @default.
• W2122262513 type Work @default.
• W2122262513 sameAs 2122262513 @default.
• W2122262513 citedByCount "19" @default.
• W2122262513 countsByYear W21222625132015 @default.
• W2122262513 countsByYear W21222625132016 @default.
• W2122262513 countsByYear W21222625132017 @default.
• W2122262513 countsByYear W21222625132018 @default.
• W2122262513 countsByYear W21222625132019 @default.
• W2122262513 countsByYear W21222625132020 @default.
• W2122262513 countsByYear W21222625132021 @default.
• W2122262513 countsByYear W21222625132022 @default.
• W2122262513 crossrefType "journal-article" @default.
• W2122262513 hasAuthorship W2122262513A5002498295 @default.
• W2122262513 hasAuthorship W2122262513A5089156165 @default.
• W2122262513 hasConcept C126322002 @default.
• W2122262513 hasConcept C143998085 @default.
• W2122262513 hasConcept C2779338263 @default.
• W2122262513 hasConcept C71924100 @default.
• W2122262513 hasConceptScore W2122262513C126322002 @default.
• W2122262513 hasConceptScore W2122262513C143998085 @default.
• W2122262513 hasConceptScore W2122262513C2779338263 @default.
• W2122262513 hasConceptScore W2122262513C71924100 @default.
• W2122262513 hasIssue "33" @default.
• W2122262513 hasLocation W21222625131 @default.
• W2122262513 hasLocation W21222625132 @default.
• W2122262513 hasOpenAccess W2122262513 @default.
• W2122262513 hasPrimaryLocation W21222625131 @default.
• W2122262513 hasRelatedWork W2039318446 @default.
• W2122262513 hasRelatedWork W2080531066 @default.
• W2122262513 hasRelatedWork W2603456398 @default.
• W2122262513 hasRelatedWork W2748952813 @default.
• W2122262513 hasRelatedWork W2897496508 @default.
• W2122262513 hasRelatedWork W2899084033 @default.
• W2122262513 hasRelatedWork W3032375762 @default.
• W2122262513 hasRelatedWork W3033465546 @default.
• W2122262513 hasRelatedWork W3108674512 @default.
• W2122262513 hasRelatedWork W3198647362 @default.
• W2122262513 hasVolume "33" @default.
• W2122262513 isParatext "false" @default.
• W2122262513 isRetracted "false" @default.
• W2122262513 magId "2122262513" @default.
• W2122262513 workType "article" @default.